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ABSTRACT
Patients with mucoepidermoid carcinoma (MEC) experience low survival rates and 
high morbidity following treatment, yet the intrinsic resistance of MEC cells to ionizing 
radiation (IR) and the mechanisms underlying acquired resistance remain unexplored. 
Herein, we demonstrated that low doses of IR intrinsically activated NFκB in resistant 
MEC cell lines. Moreover, resistance was significantly enhanced in IR-sensitive cell lines 
when NFκB pathway was stimulated. Pharmacological inhibition of the IKK-β/IκBα/
NFκB axis, using a single dose of FDA-approved Emetine, led to a striking sensitization 
of MEC cells to IR and a reduction in cancer stem cells. We achieved a major step 
towards better understanding the basic mechanisms involved in IR-adaptive resistance 
in MEC cell lines and how to efficiently overcome this critical problem. 
INTRODUCTION
Salivary gland cancer (SGC) is a relatively rare 
group of tumors, with annual incidence rates between 0.05 
to 2 new cases per 100,000 [1]. In the US, the incidence of 
SGC significantly increased from 1974–1976 to 1998–1999 
and accounted for 6.3% compared to 8.1% of all head and 
neck cancers, respectively [2]. The 5-year survival rate 
for SGC is 60–80%; however, this rate drops to 50% by 
10 years [3]. Distant metastasis, more frequently in the 
lungs, is the primary cause of death and occurs slowly, with 
patients surviving up to 20 years [1]. Mucoepidermoid 
carcinoma (MEC) is the most common malignant 
SGC, followed by adenoid cystic carcinoma [4–6]. 
Treatment for MEC derives from therapeutic protocols 
optimized for head and neck squamous cell carcinomas 
[7]. Surgical excision and ionizing radiation (IR) are the 
first-line treatment options for resectable and unresectable 
tumors, respectively. Postoperative IR is recommended 
for patients with residual disease with extensive nodal 
metastasis or capsular rupture. Postoperative radiotherapy 
is also suitable for patients with high-grade tumors and 
advanced disease, positive margins and perineural or 
vascular invasion [1]. In general, more than 80% of all 
SGC patients receive radiotherapy [8]. Although IR 
therapy used broadly to treat SGC, including MEC, little 
is known about how resistance to radiation develops in 
SGC cells. Moreover, the low survival rates that occur 
in the long-term underscore the urgent need to identify 
molecular targets that sensitize SGC cells to radiotherapy.
Nearly 50% of all cancer patients will be treated with 
IR alone or in combination with surgery or chemotherapy 
[8]. IR activates the DNA damage response pathway and 
cell cycle arrest, leading to senescence or apoptosis [9]. 
The responsiveness of the tumor to IR is substantially 
mediated by the intrinsic radiosensitivity of tumor cells 
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[10]. Fractionated radiotherapy enables normal tissues to 
recover, but it also allows the surviving fraction of tumor 
cells to proliferate, promoting long-term resistance [11]. 
Distinct pathways, such as the NFκB pathway, are triggered 
during radiotherapy. Activation NFκB leads to increased 
cellular tolerance to subsequent IR doses in various cell 
lineages, such as breast, prostate and lung cancer cells 
[12, 13]. The NFκB canonical or classical, pathway is 
activated by a pro-inflammatory stimulus, such as TNF-α, 
that triggers the activation of the IKK complex. Activated 
IKK-α and IKK-β phosphorylate IκB-α at S-32 and S-36, 
allowing NFκB to translocate to the nucleus where it acts as 
a nuclear transcription factor [14, 15]. Cancer cells normally 
have high NFκB activity, [16] leading to increased cell 
survival via antagonism of apoptotic pathways [17]. Indeed, 
the NFκB subunit RelA (p65) can promote resistance 
to programmed cell death by suppressing p53 function 
[18]. We have also show that NFκB signaling drives 
chemoresistance in head and neck squamous cell carcinoma 
by modulating chromatin modifications [19].
Previous studies showed that both low and high doses 
of IR upregulate NFκB binding activity in several types of 
solid tumors in a dose- and time-dependent manner [13, 
20, 21]. The level of NFκB in tumor cells is an important 
determinant of responsiveness to IR because NFκB induces 
resistance in several tumor models by inhibiting apoptosis 
after DNA damage [13, 22]. Activated NFκB regulates the 
transcription of over 400 genes, including Bcl-2, BcL-xL, 
XIAP, survivin and AKT, which are associated with NFkB-
driven radioresistance [23]. Recently, it was shown that IKK-β 
regulates the repair of DNA double-strand breaks induced 
by IR in breast cancer cells [15]. This evidence supports the 
use of NFκB inhibitors as adjuvant treatment to sensitize 
cancer cells to IR. In fact, promising pre-clinical results have 
been achieved in colorectal cancer [24], melanoma [25] and 
neuroblastoma [26]. Current therapeutic strategies focused 
on inhibiting NFκB signaling rely on proteasome inhibition, 
resulting in off-target effects. Identifying new drugs that 
induce selective inhibition of NFκB, by interfering with 
IKKs or by inhibiting phosphorylation and promoting loss 
of function of the IκB-alpha super-repressor, are expected to 
efficiently reduce tumor resistance. 
In our study, we explored the response of MEC cells 
to IR. We found that high intrinsic radioresistance of MEC 
cells is associated with NFκB activation. Furthermore, 
inhibition of NFκB using FDA-approved Emetine resulted 
in targeted inhibition the NFκB super-repressor IκB 
alpha. Emetine also disrupted cancer stem cells (CSC) by 
inhibiting the Ikk-β subunit and inducing apoptosis. 
RESULTS
Ionizing radiation differentially affects 
mucoepidermoid carcinoma cell lines
SGC are historically recognized to be radioresistant. 
Nevertheless, IR is widely used for the treatment of 
advanced and high-grade tumors. This historical concept 
is based on cross-sectional studies of lung cancer that 
observed poor local control rates of tumors receiving 
conventional doses of radiotherapy [27]. Little is known 
about the radiosensitivity of SGC given the small number 
of available tumor cell lines. For the first time, we 
evaluated the response of three different MEC cell lines, 
recently established at the University of Michigan School 
of Dentistry, [28, 29] using a wide range of IR doses 
(0, 2, 4, 6 and 8 Gy). Radiosensitivity differed among the 
cell lines (Figure 1A). The most sensitive MEC cell lines 
(UM-HMC-3A and UM-HMC-3B) had a survival fraction 
at 2 Gy (SF2) of 0.81 while UM-HMC-5 had an SF2 of 
0.97. Previous studies have shown that other carcinomas 
cells, such as cervical squamous cell carcinoma, have 
a much lower SF2 (0.27 to 0.75) compared to our MEC 
cell lines [30]. Despite UM-HMC-3A and UM-HMC-3B 
cells having similar SF2 values, the metastatic lymph 
node UM-HMC-3B cells had increased resistance to IR at 
intermediate levels of radiation (4 and 6 Gy, ***p < 0.001) 
(Figure 1A).
To further characterize the resistance phenotype 
observed in MEC cells, we examined their proliferation 
in response to various doses of radiation. To our surprise, 
UM-HMC5 radioresistance phenotype was directly 
associated with the maintenance of basal levels of cellular 
proliferation, as measured by Ki67 (Figure 1B). Reduced 
proliferation was only observed in response to high 
doses of IR (8 Gy, *p < 0.05). We observed a statistically 
significant reduction in proliferation at smaller doses of 
IR (4 Gy and 6 Gy) in UM-HMC-3A and UM-HMC-3B 
cells, respectively. Interestingly, a low dose of IR (2 Gy) 
induced an increase in the number of abnormal mitotic 
figures in UM-HMC-5 cells that is defined by the presence 
of multipolar, ring, dispersed, asymmetrical and lag-type 
mitoses (Supplementary Figure S1).
Mucoepidermoid carcinomas express high basal 
levels of NFκB
NFκB is a crucial player in several steps of cancer 
initiation and progression, primarily due to its strong anti-
apoptotic effect in cancer cells [31]. In most cell types, 
NFκB dimers are predominantly inactive in the cytoplasm; 
however, cancer cells typically have high NFκB activity 
[16]. We analyzed the protein expression of nuclear NFκB 
(active form) in human samples of MEC and normal 
salivary gland (NSG). Interestingly, although NFκB is 
predominantly cytoplasmic in NSG samples (Figure 2A 
arrowhead; mean 0.5% of nuclear staining/sample), all 
MEC samples were positive for nuclear NFκB (10.1% 
– 20.5% of nuclear staining/sample) (Figure 2A arrow). 
Further, we have explored the presence and localization 
of NFκB in our MEC cell lines. Similar to the observed 
in paraffin sections of human MEC tumors, all cell lines 
expressed nuclear NFκB (Figure 2B). Nuclear NFκB 
is associated with poor prognosis in several cancers, 
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including rectal [32], esophageal [33] and head and 
neck cancers [34]. In adenoid cystic carcinomas, NFκB 
expression is considered an independent prognostic factor 
associated with poor overall survival [35]. Although no 
clinical association could be established in our samples, 
the increase in active NFκB suggests that this pathway 
plays a role in MEC behavior. However, it is unknown 
whether high basal levels of NFκB are associated with 
resistance to radiotherapy in MEC. 
IR induces accumulation of NFκB and activation 
of the NFκB signaling pathway induces IR 
resistance
To better understand the correlation between 
NFκB expression and tumor resistance to radiotherapy, 
we examined the effects of IR on NFκB activity in 
MEC. We exposed our three MEC cell lines to 2 Gy of 
radiation, which is the daily faction dose recommended 
for MEC patients receiving radiotherapy [1]. As revealed 
by Western Blotting, all MEC cell lines had detectable 
levels of NFκB at baseline (0 Gy), corroborating to our 
findings from patient samples that showed detectable 
levels of NFkB. Interestingly, 2 Gy IR-induced the 
accumulation of NFκB in UM-HMC-5, but had no effect 
on NFκB in UM-HMC-3A and UM-HMC-3B (Figure 2C, 
*p < 0.05), corroborating to our previous finding that 
UM-HMC-5 have a higher resistance profile. Notably, 
our findings suggest that certain MEC patients may not 
benefit from fractionated radiotherapy; in contrast, 2 Gy 
IR may stimulate radio-adaptive resistance through NFκB 
signaling. In addition, administration of the clinically 
relevant 2 Gy dose resulted in a substantial increase in 
mitosis, including the presence of aberrant mitotic figures 
(Supplementary Figure S1, arrows **p < 0.01). 
We next explored whether upregulation of NFκB 
directly influences MEC resistance to IR. Active NFκB 
signaling induces anti-apoptotic proteins, resulting in 
tumor cells evading radiotherapy [12]. Using a clonogenic 
assay, we found that stimulation of the NFκB pathway 
using TNF-α led to increased resistance of UM-HMC-3A 
and UM-HMC-3B tumor cells to IR (Figure 2D). 
Interestingly, UM-HMC-5, which previously showed 
elevated radioresistance (Figure 1A) and NFκB levels 
(Figure 2C NS p > 0.05, *p < 0.05) in response to IR, did 
not benefit from TNF-α (Figure 2D). We observed that 
NFκB activation markedly increased the resistance of 
MEC cell lines to IR. In response to all IR doses, UM-
HMC-3A and UM-HMC-3B cells stimulated with TNF-α 
were more resistant than the control (Figure 2D, NS 
Figure 1: Intrinsic resistance of MEC cells to IR. (A) Clonogenic survival was measured 7 days after IR (0–8 Gy). The data are 
expressed as mean ± SD (n = 3) of survival fraction compared to nonirradiated cells. Colonies consisting of more than 50 cells were scored 
as surviving colonies. (B) Cells were stained for Ki67 24 hrs after IR, scored for positive nuclear staining and presented as a percentage of 
the total cell number (n = 3).
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p > 0.05, **p < 0.01, ***p < 0.001). Our findings suggest 
that UM-HMC-5 cell respond to low doses of radiation by 
inducing the activation of the NFκB signaling pathway, and 
that administration of TNF-α does little to further activate 
the NFκB signaling on UM-HMC-5 when compared to 
the UM-HMC-3A and 3B cell lines. Although we have 
established a correlation between the NFκB pathway and 
MEC resistance to radiotherapy, the clinical relevance of 
inhibiting this pathway in MEC is unknown. 
In search for a potential mechanism associated with 
increased resistance to chemotherapy of UM-HMC-5 cell 
line, we explored the p53 status of our MEC cell lines. We 
used a phospho-p53 antibody phosphorylated at the serine 
15 that is associated with p53 gain of function (active). 
Indeed, we found that p53 is highly expressed in UM-
HMC-5 cell line compared to UM-HMC-3A and 3B cells 
in which the p53 levels could not be detected (Figure 2E). 
Similar to the accumulation of phosphorylated p53 protein, 
the total amount of p53 protein (not phosphorylated) was 
also very high compared to UM-HMC-3A and 3B. It 
has been demonstrated that p53 gain of function is often 
associated with mutations and constitutive expression of 
mutant p53 interferes with the process of apoptosis, a 
major and essential event for the success of any anticancer 
treatment. While p53 wild type cell lines are more 
sensitive to DNA damaging agents, mutant p53 confers 
resistance to DNA-damage related apoptosis [36]. Besides, 
p53 protein is responsible for prolonged arrest following 
IR exposure, thereby facilitating the DNA repair in the 
absence of apoptosis [37]. The absence of p53 observed 
in UM-HMC-3A and 3B cell lines support the notion that 
tumors presenting inactivate p53 lack the ability to repair 
the DNA. Lack of p53, and increased sensitive to DNA-
damage result in mitotic catastrophe, the main antitumor 
mechanism associated to irradiation [37].
Emetine-induced inhibition of NFκB is mediated 
by downregulation of IκB-α/IKK-β and p21
Targeted inhibition of NFκB is a promising 
novel adjuvant treatment for sensitizing cancer cells to 
radiotherapy. Encouraging results have been reported in 
different solid tumors, such as colorectal [24] and prostate 
[38] cancer. However, FDA-approved NFκB inhibitors, 
such as Bortezomib, are proteasome inhibitors that 
target the multi-catalytic proteinase complex involved 
in protein degradation. Inhibitors like Bortezomib 
downregulate NFκB but also increase targeted activity 
of cell cycle proteins and apoptosis-associated pathways 
[39]. Recently, Emetine, a drug purified from the ipecac 
root, was shown to be a novel selective inhibitor of NFκB 
[40]. FDA-approved Emetine has emetic properties and 
has been used for decades to treat protozoan infections. 
Emetine selectivity inhibits IκBα phosphorylation at 
Ser32, thereby preventing NFκB from translocating to the 
nucleus and altering gene expression [40]. We assessed the 
ability of Emetine to inhibit the NFκB pathway in MEC 
tumor cells. We found that Emetine efficiently reduced 
phosphorylated IκB-α and NFκB protein (Figure 3A). 
Surprisingly, Emetine downregulated IKK-β, but not 
IKK-α, subunit protein (Figure 3A). IKK-β activation 
triggers the canonical NFκB pathway [41] and regulates 
several pro-survival and anti-apoptotic genes, including 
Bcl2, Bcl-XL, and XIAP [42]. Interestingly, the effect of 
Emetine on IKK-β has not been observed in other systems. 
Our results also demonstrated that Emetine downregulated 
p21 expression. Although earlier studies suggested that 
p21 suppresses cancer through promotion of cell cycle 
arrest, cellular differentiation, and senescence, recent 
studies suggest that p21 induces proliferation and cellular 
transformation and is associated with poor prognosis in the 
prostate, ovarian, cervical, breast, brain, and esophageal 
squamous cell carcinomas [43–50]. Indeed, MEC tumor 
cell lines expressing p21 (Figure 3B) failed to activate 
senescence (Figure 3C), as measured by p16ink4 levels, in 
basal conditions and following administration of Emetine, 
suggesting that p21 acts as an oncogene in MEC, as it 
does in other cancers. Supporting our findings, Emetine 
downregulated p65 and IKK-β and further suppressed 
p21, leading to reduced colony formation in all analyzed 
MEC cell lines (Figure 3D, *p < 0.05; **P < 0.01). 
Although we have not assessed if p53 is mutated in our 
cell lines, the data show an interesting pattern previously 
demonstrated by the group of Manuel Serrano in head and 
neck cancers, in which high levels of p21 do not correlate 
to p53 levels but does correlate with better survival 
rates [51], and in our case, more sensitize tumor cells to 
radiation (UM-HMC3A and 3B). In Ovarian cancer, the 
group of Berchuck has shown that the presence of mutated 
p53 is usually associated with decreased p21 expression 
[52]. Our findings suggest a potential p53 dependent 
mechanism associated to UM-HMC-5 resistance to 
radiotherapy. Notably, MEC cells are sensitive to NFκB 
inhibition, suggesting tumor progression is dependent on 
this pathway. Indeed, as compared to UM-HMC3A and 
UM-HMC5 cells, the metastatic UM-HMC3B cells were 
so sensitive to Emetine that we could not identify the 
formation of tumor colonies (Figure 3D). Impaired colony 
formation was due, in part, to the activation of apoptosis 
in UM-HMC3B cells, as shown by the SubG0/G1 peak 
during cell cycle analysis (Figure 3E).
Inhibition of the IKK-β/IκB-α/NFκB signaling 
axis sensitizes MEC cells to IR
Following our previous finding that activation of 
the NFκB pathway increases MEC resistance to IR, we 
hypothesized that inactivation of the pathway by Emetine 
would sensitize cells to IR. To test this hypothesis, we treated 
all cell lines with Emetine 24 hours before irradiation. To 
properly understand the therapeutic efficacy of Emetine as 
a sensitizing agent, we removed Emetine from the culture 
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media prior to irradiation (Figure 4A). Tumor cells were 
allowed to grow for 7 days before we assessed colony 
formation. Control tumor cells received radiation alone. 
We observed major declines in the surviving fraction at 
all IR doses when NFκB was inhibited prior to irradiation 
(Figure 4B). When UM-HMC-3A and UM-HMC-5 were 
sensitized with Emetine, we achieved a mean improvement in 
the SF2 of 24.8%. UM-HMC5 cells, originally very resistant, 
were sensitized to irradiation following NFκB inhibition 
(Figure 4B). Collectively, our data suggests that NFκB 
activation promotes IR resistance, and that pharmacological 
inhibition of NFκB sensitizes MEC cells to IR.
Figure 2: Activation of NFκB in MEC. (A) NFκB (p65) (yellow arrows) was significantly increased in the nucleus of MEC samples 
compared to normal salivary glands, which showed prevalent cytoplasmic staining (arrowhead) (***p < 0.001, n = 11, mean ± SD). 
(B) Immunofluorescence of UM-HMC-3A, UM-HMC-3B, and UM-HMC-5 tumor cell lines depict the presence of nuclear NFκB (yellow 
arrows). (C) UM-HMC-3A, UM-HMC-3B, and UM-HMC-5 show detectable NFκB (p65) protein levels at baseline (0 Gy). NFκB is 
increased in UM-HMC-5 following 2 Gy of IR (*p < 0.05, mean ± SD from experiments run in triplicate). (D) Clonogenic assay for MEC 
cells with no stimuli or TNF-α stimuli revealed that NFκB upregulation significantly increases the resistance of UM-HMC-3A and UM-
HMC-3B (**p < 0.01, ***p < 0.001, n = 3, mean ± SD compared to 0 Gy). (E) Western blot of UM-HMC-3A, UM-HMC-3B, and UM-
HMC-5 for phosphorylated p53 (ser15) depict high expression of the p53 protein on UM-HMC-5 cells. UM-HMC-3A and 3B are absent 
of p53 protein levels. 
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Emetine-induced inhibition of the IKK-β/IκB-α/
NFκB signaling axis potentialize the ability of IR 
to deplete MEC cancer stem cells (CSCs)
Among the mechanisms involved in the acquisition 
of resistance in cancer cells are the activation of NFκB 
signaling and the presence of CSCs [53–55]. CSCs 
represent a subset of tumor cells that have stem cell-
like proprieties, such as self-renewal and multipotency. 
Recently, Adams et al. demonstrated that MEC contains 
a small population of CSCs with enhanced tumorigenic 
potential [29]. Both NFκB and CSCs are closely 
interrelated and inhibition of the NFκB pathway blocks the 
expression of genes associated with stem cells, including 
Nanog and Sox2 in mammary cells [56]. Furthermore, 
canonical and noncanonical NFκB signaling drives CSC 
maintenance in breast cancer cells [57]. We found that 
targeted inhibition of NFκB resulted in sensitization of 
MEC tumor cells to IR (Figure 4B), but we did not know 
whether Emetine would affect CSCs. Using a similar 
approach described earlier, we administered Emetine 
24 hours before IR (Figure 5A). Seven days after IR, 
Figure 3: Emetine induces inhibition of the IKK-β/IκB-α/NFκB axis and induces apoptosis of UM-HMC-3B. (A) Down-
regulation of NFκB expression in MEC cells after Emetine treatment for 24 hrs was confirmed by Western blot analysis. Emetine inhibited 
IκB-α (Ser32) and IKK-β phosphorylation but did not affect the IKK-α subunit. (B) Emetine treatment for 24 hrs lead to p21 inhibition, 
and (C) had no effect on p16. (D) Emetine disrupted the colony forming potential of MEC cells. UM-HMC-3A and UM-HMC-5 treated for 
24 hrs with Emetine had a significantly smaller number of colonies after 7 days in culture while UM-HMC-3B did not have colonies larger 
than 50 cells. (E) Emetine causes cell cycle arrest at the sub G0/G1 checkpoint in UM-HMC-3B cells (*p < 0.05).
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tumor cells were collected and processed for ALDH 
enzymatic activity using fluorescence-activated cell 
sorting (FACS). Interestingly, combined administration of 
Emetine and IR resulted in further depletion of CSCs in all 
MEC tumor cells compared to radiation alone (Figure 5B). 
Radiation alone failed to reduce CSCs in UM-HMC3B 
cells (ns p > 0.05) and only slightly, but significantly, 
reduced CSCs in UM-HMC3A cells (*p < 0.05). However, 
sensitizing the cells with Emetine resulted in a significant 
reduction in CSCs in UM-HMC3A and UM-HMC3B 
MEC cells compared to controls (0 Gy) (**p < 0.01). 
CSCs were significantly reduced in UM-HMC5 cells in 
response to radiation alone compared to controls (0 Gy) 
(***p < 0.001); nonetheless, Emetine further reduced 
CSCs in UM-HMC5 cells (Figure 5B ***p < 0.001). Our 
findings demonstrate that inhibition of the NFκB signaling 
pathway in MEC tumors is an effective therapeutic 
strategy to sensitize tumor cells to radiation independent 
of the initial resistance of each cell line to radiation.
DISCUSSION
MEC represents the most common malignant SGC 
[4–6]. In contrast to other glandular tumors, significant 
advances in treatment and overall survival for SGC 
patients have not improved in the last three decades. 
Surgery remains the first-line therapy option for MEC. 
Tumors located in the parotid gland usually require 
superficial or radical parotidectomy for infiltrative 
cases, compromising the maintenance of the facial nerve 
[1]. For minor SGC, commonly located in the palate, 
maxillectomy is typically required [58]. The amount of 
sequels and high morbidity, which is associated with low 
survival rates over long-term periods, underscore the need 
to identify therapies that improve survival and quality of 
life. It is estimated that more than 80% of SGC patients 
will need radiotherapy as first-line or adjuvant therapy 
[8]. However, both intrinsic resistance of MEC cells to IR 
and the basic mechanisms underlying acquired resistance 
remain unexplored. We have provided initial evidence 
regarding the molecular response of MEC cells to IR. We 
showed that radioresistance of MEC is NFkB-dependent 
and that targeting this pathway with Emetine improves 
the efficiency of IR in vitro. Administering a single dose 
of Emetine before IR sensitizes the majority of the tumor 
cells, including CSCs. 
Emetine is a natural crystalline alkaloid found 
in ipecac syrup, which is derived from Psychotria 
ipecacuanha. Emetine has been widely used to treat 
amoebiasis since the early 1900s [59]. The earliest report 
describing the use of Emetine as an anti-neoplastic drug 
dates to 1918; however, Phase I/II clinical trials using 
emetine were not performed by the NCI until the mid-1970s 
[60–62]. Due to disparate results with Emetine, ranging 
from no clinical benefit to disease stabilization/tumor 
regression, it was not widely studied for its anti-neoplastic 
properties for many years. It was not until the 2000s that 
new reports examining the effect of Emetine on neoplastic 
cells emerged [63–69]. The identification of new therapeutic 
applications of already approved drugs is referred to as drug 
repurposing. Given that 80% of new drugs that enter human 
clinical testing are never approved for use, repurposing 
has the advantages of reduced safety risks, faster access 
to treatment and decreased cost [70, 71]. Because more 
Figure 4: Pharmacological inhibition of NFκB sensitizes MEC cells to IR. (A) Cells were sensitized with Emetine for 24 hrs 
before IR. The drug was removed before IR exposure, and the clonogenic assay was performed after 7 days. (B) Survival was significantly 
decreased in UM-HMC-3A and UM-HMC-5 sensitized with Emetine compared to vehicle (n = 3, mean ± S, D compared to 0 Gy). 
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than $90 billion is spent on the development of oncology 
drugs, and it takes more than 14 years for a promising new 
molecule to be translated to an approved drug, the National 
Center for Advancing Translational Sciences (NCATS) at 
NIH in funding projects that can provide Phase I/II proof-of-
principle data using repurposed drugs [72]. Previous studies 
demonstrated that Emetine induces apoptosis in ovarian 
carcinoma [66], leukemic [64] and pancreatic cells [69] and 
arrests growth of bladder cancer cells [67]. Moreover, the 
daily subcutaneous dose of 1 mg/kg Emetine does not cause 
toxicity in patients [61], highlighting its safety in humans. 
A recent study by Miller et al. showed that Emetine inhibits 
IκB-α phosphorylation [40] but, to our knowledge, we are 
the first to examine this effect in cancer treatment. 
Reactive oxygen species (ROS) and increased 
DNA damage triggered by IR activates nuclear ataxia 
telangiectasia mutated (ATM) signaling, resulting in 
activation of the IKK complex [12]. An active IKK complex 
induces IκB degradation and translocation of NFκB to the 
nucleus [16]. In the early 2000s, it was found that NFκB 
activation is associated with radioresistance in breast 
cancer cells following fractionated IR treatment [73, 74]. 
A recent study showed that NFκB activation protects from 
radiation in human Ewing sarcoma, neuroblastoma, breast, 
bladder, colon, prostate and lung cancer cells. In this study, 
high doses of IR (4 Gy) induced cell death; nevertheless, a 
previous study showed that sub-lethal doses of IR (2, 10, 50 
or 100 cGy) induced NFκB activation and prevented cell 
death compared to higher doses of IR [13]. We demonstrated 
that a low-dose of IR (2 Gy) activated NFκB in the most 
resistant MEC cell line. Further, when the NFκB pathway 
was activated in MEC cells through a TNF-α stimulus, 
resistance was enhanced in the most IR-sensitive cell lines. 
These findings significantly advance our understanding of 
IR-adaptive resistance in MEC cells, a field not previously 
explored. Also, our findings suggest that radioresistant MEC 
tumors are likely to respond to radiation by overexpressing 
NFκB signaling to levels that confer radioresistance, similar 
to the achieved upon administration of TNF-α (Figure 2D). 
Inhibition of NFκB signaling in combination with IR may 
be a novel treatment for MEC. We showed that disrupting 
the NFκB pathway using Emetine before IR significantly 
increased the sensitivity of MECs to IR and that Emetine 
combined with IR decreased CSCs. 
CSCs are a subset of tumor cells that self-renew and 
are multipotent with the ability to generate heterogeneous 
lineages of neoplastic cells that comprise the tumor. 
Thus, treatment will only be successful if it destroys 
Figure 5: A combination of NFκB inhibition and IR efficiently deplete CSCs. (A) Cells were sensitized with Emetine for 24 hrs; 
Emetine was removed from the media before IR. Cells were collected and processed for ALDH enzymatic activity using fluorescence-
activated cell sorting (FACS). (B) A combination of NFκB inhibition and IR leads to enhanced depletion of CSCs in MEC cell lines 
compared to radiation alone (n = 3, mean ± SD).
Oncotarget73040www.impactjournals.com/oncotarget
CSCs, and this needs to be considered when optimizing 
anti-neoplastic drugs so as not to underestimate curative 
potential. Numerous findings suggest that intrinsic tumor 
radioresistance is associated with a higher proportion of 
CSCs [75–77]. Kurth et al. found that ALDH+ head and 
neck cancer cells maintain their tumorigenic properties 
after irradiation, increasing the chances of recurrence [54]. 
Failure to eradicate CSCs after IR may result in tumor 
recurrence and neoplastic cell dissemination, leading 
to local or distant metastasis. IR alone had no effect on 
CSCs in our metastatic cell line (UM-HMC-3B), which 
is alarming given that one of the main indications for IR 
treatment in MEC patients is the presence of advanced 
disease [1]. Targeting NFκB to disrupt CSCs is based on 
evidence that inhibition of NFκB downregulates genes 
associated with stemness proprieties, such as Nanog and 
Sox2 [56]. By sensitizing MEC cells to IR using Emetine, 
we were able to eradicate CSCs. Our findings strongly 
support the combination of NFκB inhibition and IR as a 
promising treatment option for MEC patients because it 
targets the bulk of the tumor in addition to CSCs.
To establish new strategies that improve the efficacy 
of IR, we must understand the biological factors involved 
in radiotherapy outcomes. While various pathways have 
been associated with radioresistance in different types of 
tumors, we must consider tumor specificity. Certain tumor 
types may benefit from a specifically targeted inhibition that 
is not successful in other types of tumors. Until now, the 
mechanisms underlying MEC radioresistance were unknown. 
We showed that sensitizing MEC cells with Emetine 
improved the SF2, the most relevant IR dose in the clinic, 
by 24.8%. Tumor control rates can be improved by 5–30% 
by increasing the effective dose IR by just 10% (reviewed in 
[22]). Our study highlights the importance of Emetine as a 
sensitizer agent to radiation. Although these results bring an 
encouraging and promising therapeutic strategy to manage 
MEC patients, it’s important to emphasize that in vivo studies 
are necessary to confirm our preliminary data.
MATERIALS AND METHODS
Human tissue specimens
Cases of MEC diagnosed between January 1995 
and December 2010 were retrieved from archives of the 
Pathology Service of Clinic Hospital in Porto Alegre, 
Rio Grande do Sul, Brazil (Human Research Ethics 
Committee approval: 11739012.1.0000.5327). The 
original hematoxylin-eosin stained slides were reviewed 
to confirm the diagnosis. 
Immunohistochemistry 
MEC samples were sectioned into 3-µm sections, 
deparaffinized in xylene and hydrated in descending 
grades of ethanol. Endogenous peroxidase activity was 
blocked using 5% hydrogen peroxide in two 15-minute 
baths. The avidin-biotin blocking kit was used to 
block nonspecific binding (Kit Vector Laboratories, 
Burlingame, CA, USA). Slides were incubated overnight 
with anti- NFκB p65 (BD Biosciences, Mountain View, 
CA, USA) and then incubated with diaminobenzidine 
tetrahydrochloride (DAB, Sigma-Aldrich, St. Louis, MO, 
USA) and counterstained with Mayer’s hematoxylin.
Cell lines
MEC cell lines UM-HMC-3A, UM-HMC-3B and 
UM-HMC-5, were initially described by Warner et al. 
(2013). Cells were maintained in a 5% CO2 humidified 
incubator at 37ºC and cultured in RPMI 1640 (Thermo 
Scientific, Waltham, MA, USA) supplement with 10% 
Fetal Bovine Serum (Thermo Scientific), 1% antibiotic 
(Invitrogen, Carlsbad, CA, USA), 1% L-glutamine 
(Invitrogen), 20 ng/ml epidermal growth factor (Sigma–
Aldrich), 400 ng/ml hydrocortisone (Sigma–Aldrich) and 
5 µg/ml insulin (Sigma–Aldrich). UM-HMC-3A, UM-
HMC-3B, and UM-HMC-5 were treated with 0.10 μM, 
0.26 μM, and 0.08 μM of Emetine dihydrochloride hydrate 
(Sigma–Aldrich), respectively, and 10 ng/ml of TNF-α 
(PeproTech, Rocky Hill, NJ, USA). 
Ionizing radiation (IR)
Ionizing radiation (IR) was performed at a dose of 
approximately 2 Gy/min using a Philips RT250 (Kimtron 
Medical, Oxford, CT, USA) in the University of Michigan 
Comprehensive Cancer Center Experimental Irradiation 
Core (Ann Arbor, MI). Dosimetry was performed using 
an ionization chamber connected to an electrometer 
system that is directly traceable to a National Institute of 
Standards and Technology calibration.
Clonogenic survival assay 
For the clonogenic assay, cells were plated into 
6-well cell culture plates at a concentration previously 
determined by plating efficiency. After overnight 
incubation, cells were exposed to a range of IR doses 
with or without pretreatment, as indicated in individual 
experiments. The cells were allowed to grow for an 
additional 7 days to form colonies and then stained with 
0.1% crystal violet. Colonies with more than 50 cells were 
counted as surviving colonies and normalized with the 
colony number observed in nonirradiated cells. 
Immunofluorescence
Cells were placed on glass coverslips in 6-well 
plates. After the indicated treatment, cells were fixed with 
absolute methanol at −20°C for 5 min. Cells were blocked 
in 0.5% (v/v) Triton X-100 in PBS and 3% (w/v) bovine 
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serum albumin (BSA) and then incubated with anti-Ki67 
(MIB-1) (Dako, Glostrup, Denmark) or anti-p65 (ser15, 
Cell Signaling Technology). Cells were then washed three 
times, incubated with FITC-conjugated secondary antibody 
and stained with Hoechst 33342 for visualization of DNA 
content and mitotic figures. Images were taken using a 
QImaging ExiAqua monochrome digital camera attached 
to a Nikon Eclipse 80i Microscope (Nikon, Melville, NY, 
USA) and visualized with QCapturePro software.
Immunoblotting
Cells were harvested in RIPA buffer and briefly 
sonicated. Protein lysates were separated by 10% to 15% 
SDS–PAGE and transferred to a polyvinyl difluoride 
membrane (Immobilon) (Millipore, Billerica, MA, USA). 
Membranes were blocked in 0.1 M Tris (pH 7.5), 0.9% 
NaCl and 0.05% Tween-20 (TBS-T) with 5% nonfat dry 
milk. Membranes were incubated with anti-phospho-
NFκB p65 (Ser536) or (ser15) (Cell Signaling), anti-
phospho-IκB-α (Ser32) (Cell Signaling), anti-IKK-α 
(p45) (Millipore), anti-IKK-β (Millipore), anti-p16 (BD 
Biosciences), anti-p21 (BD Biosciences), anti-p53 (Ser15) 
(Cell Signaling), and anti-p53 (Cell Signaling, clone 7F5). 
GAPDH (Millipore) served as a loading control. The 
reaction was visualized using ECL SuperSignal West Pico 
Substrate (Pierce Biotechnology, Waltham, MA, USA). 
Flow cytometry 
Cell cycle distribution was accessed by propidium 
iodide staining. After treatment with Emetine, cells were 
harvested and fixed with 70% ethanol on ice for 2 hours. 
The cell pellet was resuspended in 0.5 mL PBS containing 
0.25% Triton X-100 for permeabilization and incubated 
for 15 minutes on ice. Cells were then incubated with 
PBS containing propidium iodide (Sigma-Aldrich; 20 μg/
mL) and RNase solution (Sigma-Aldrich; 10 μg/mL) for 
30 minutes at room temperature. The relative number of 
cells in different phases of the cell cycle were assessed by 
flow cytometry, and the percentages of cells in subG0/G1, 
G1, S and G2 were calculated. 
MEC cancer stem cell-like cells were identified 
by aldehyde dehydrogenase (ALDH) activity using flow 
cytometry. The Aldefluor kit (StemCell Technologies, 
Durham, NC, USA) was used according to the 
manufacturer’s instructions to identify cells with high 
ALDH enzymatic activity. Cells with or without 
pretreatment, as indicated in individual experiments, were 
suspended with activated Aldefluor substrate (BODIPY 
amino acetate) or negative control (dimethylamino 
benzaldehyde, a specific ALDH inhibitor) for 45 minutes 
at 37°C. All samples were analyzed using a FACS Canto 
IV (BD Biosciences) at the University of Michigan Flow 
Cytometry Core.
Statistical analysis
All statistical analysis was performed using 
GraphPad Prism (GraphPad Software, San Diego, CA). 
Statistical analysis of the mitosis assay, Ki67 staining, 
and flow cytometry were performed by one-way analysis 
of variance (ANOVA) followed by Tukey’s multiple 
comparison tests. Asterisks denote statistical significance 
(*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; 
and NS p > 0.05).
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